Evaluation of the Agata Sepsis® Platform for Molecular Diagnosis of Sepsis in Hospitalized Patients - Takeaways - MDSpire

Evaluation of the Agata Sepsis® Platform for Molecular Diagnosis of Sepsis in Hospitalized Patients

  • By

  • María Guadalupe Moreno-Treviño

  • Francisco González-Salazar

  • Rafael Baltazar Reyes León-Cachón

  • Gerardo Rivera-Silva

  • Mayra Ivonne Hernández-Coria

  • Javier Acedo-Zúñiga

  • Ivan Alejandro de la Peña-Mireles

  • José Luis Elizondo-Murillo

  • Claudio Garibay-Orijel

  • February 4, 2026

  • 0 min

Share

  • 1

    Sepsis is a severe condition with a high mortality rate, affecting over 40 million people globally and causing 11 million deaths annually.

  • 2

    In Mexico, sepsis accounts for over 230,000 cases and approximately 40,000 deaths each year, with a mortality rate of 9.39% in hospitalized patients.

  • 3

    Early diagnosis of sepsis can significantly reduce the progression to septic shock and multiorgan failure, emphasizing the need for accurate diagnostic tools.

  • 4

    The Agata Sepsis® Platform offers rapid identification of sepsis-causing bacteria, reducing culture positivity time to about 4 hours compared to traditional methods.

  • 5

    Next-Generation Sequencing and advanced diagnostic tools like the Agata Sepsis® Platform are crucial for improving sepsis management and patient outcomes.

Original Source(s)

Evaluation of the Agata Sepsis® Platform for Molecular Diagnosis of Sepsis in Hospitalized Patients

  • by María Guadalupe Moreno-Treviño, Francisco González-Salazar, Rafael Baltazar Reyes León-Cachón, Gerardo Rivera-Silva, Mayra Ivonne Hernández-Coria, Javier Acedo-Zúñiga, Ivan Alejandro de la Peña-Mireles, José Luis Elizondo-Murillo, Claudio Garibay-Orijel

  • February 4, 2026

Related Content

Off by a beat: the effects of temporal misalignment in reinforcement learning for sepsis treatment

Aspirin is associated with improved outcomes in sepsis patients with atrial fibrillation: an analysis of the MIMIC-IV and eICU-CRD databases

Beyond demographic tables: integrating data quality in clinical trial representativeness